^
Association details:
| Biomarker: | KRAS G13A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | everolimus (mTOR inhibitor) + avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I trial of the RAF/MEK clamp VS-6766 in combination with everolimus using an intermittent schedule with expansion in NSCLC across multiple KRAS variants.
Published date:
05/26/2022
Excerpt:
In the KRAS mt NSCLC expansion cohort, 10 patients are evaluable for efficacy and 2 confirmed responses were reported (KRAS mutations G12V and G13A) with an objective response rate (ORR) 20% to date….The median progression free survival (PFS) in the KRAS mt NSCLC cohort is 6.35 months (95% CI 3.52 – not reached)....The combination of VS-6766 with everolimus has shown activity in patients with a variety of KRAS mutation variants including responses in KRAS mt NSCLC.
DOI:
10.1200/JCO.2022.40.16_suppl.9018
